BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30231393)

  • 1. Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.
    Jain N; Thompson P; Ferrajoli A; Nabhan C; Mato AR; O'Brien S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():580-591. PubMed ID: 30231393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapies in CLL: Monotherapy Versus Combination Approaches.
    Khan M; Siddiqi T
    Curr Hematol Malig Rep; 2018 Dec; 13(6):525-533. PubMed ID: 30535947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
    Cheson BD
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):723-727. PubMed ID: 28780145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
    Hilal T; Gea-Banacloche JC; Leis JF
    Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.
    Mauro FR; Caputo MD; Rosati S; Pepe S; De Benedittis D; De Luca ML; Foà R
    Expert Rev Hematol; 2018 Aug; 11(8):601-611. PubMed ID: 29969322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
    Bachow SH; Lamanna N
    Curr Hematol Malig Rep; 2016 Feb; 11(1):61-70. PubMed ID: 26951237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Treatment of Chronic Lymphocytic Leukemia.
    Jamroziak K; Puła B; Walewski J
    Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment approaches in CLL: Challenges and opportunities in the elderly.
    Eichhorst B; Hallek M; Goede V
    J Geriatr Oncol; 2016 Sep; 7(5):375-82. PubMed ID: 27491497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
    Marini BL; Samanas L; Perissinotti AJ
    J Oncol Pharm Pract; 2017 Oct; 23(7):502-517. PubMed ID: 27357816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in the treatment of chronic lymphocytic leukaemia].
    Mozas P; Delgado J
    Med Clin (Barc); 2016 Nov; 147(10):447-454. PubMed ID: 27431885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
    Rossi D; Gerber B; Stüssi G
    Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
    Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
    Yeung CCS; Shadman M
    Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options.
    Sharma S; Rai KR
    Cancer; 2019 May; 125(9):1432-1440. PubMed ID: 30807655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease in chronic lymphocytic leukaemia.
    García Vela JA; García Marco JA
    Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies].
    Kojima K
    Rinsho Ketsueki; 2020; 61(9):1275-1280. PubMed ID: 33162526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.